Select Page

BURLINGTON, Vt., Sept. 08, 2020 (GLOBE NEWSWIRE) — CoreMap, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) to support development of technology aimed at expanding treatment opportunities for patients with Atrial Fibrillation (AF).   AF is the most common and complex cardiac arrythmia affecting 33 million patients globally. Patients are at severe risk of complications including stroke, heart attack and death. AF patients have limited treatment options and medications are effective approximately half of the time. Ablation is highly effective at treating other arrythmias, but current mapping technologies are too limited to provide curative patient-specific treatment for chronic AF.About CoreMap
CoreMap is developing advanced diagnostic technology to enable electrophysiologists to make more informed therapeutic decisions and improve patient outcomes. Our technologies will allow for patient-specific treatments, because when treating patients with AF, ‘one size does not fit all.’ For more information, visit